{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T21:09:19Z","timestamp":1788815359824,"version":"build-2803163510"},"reference-count":58,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,9,1]],"date-time":"2026-09-01T00:00:00Z","timestamp":1788220800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["international-journal-of-gynecological-cancer.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["International Journal of Gynecological Cancer"],"published-print":{"date-parts":[[2026,9]]},"DOI":"10.1016\/j.ijgc.2026.104839","type":"journal-article","created":{"date-parts":[[2026,6,27]],"date-time":"2026-06-27T23:04:18Z","timestamp":1782601458000},"page":"104839","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":0,"title":["Biomarkers guiding fertility-sparing treatment in endometrial cancer"],"prefix":"10.1016","volume":"36","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5134-4466","authenticated-orcid":false,"given":"Andrej","family":"Cokan","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-1574-6572","authenticated-orcid":false,"given":"Tibor A.","family":"Zwimpfer","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9395-0627","authenticated-orcid":false,"given":"David","family":"Viveros-Carre\u00f1o","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Khayal","family":"Gasimli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0956-1050","authenticated-orcid":false,"given":"Ilker","family":"Kahramanoglu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7613-8354","authenticated-orcid":false,"given":"Houssein","family":"El Hajj","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martina Aida","family":"Angeles","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4499-6543","authenticated-orcid":false,"given":"Esra","family":"Bilir","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Nicol\u00f3","family":"Bizzarri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrea","family":"Rosati","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6598-0896","authenticated-orcid":false,"given":"Zoia","family":"Razumova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tanja","family":"Nikolova","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7207-7213","authenticated-orcid":false,"given":"Manuela","family":"Ludovisi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0400-0046","authenticated-orcid":false,"given":"Maximilian Heinz","family":"Beck","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4886-3481","authenticated-orcid":false,"given":"M\u00e1rton","family":"Keszthelyi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Maja","family":"Paki\u017e","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"3","key":"10.1016\/j.ijgc.2026.104839_bib1","first-page":"229","article-title":"Global cancer statistics 2022: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries","volume":"74","author":"Bray","year":"2024","journal-title":"CA Cancer J Clin"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104839_bib2","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1186\/s12905-023-02535-5","article-title":"Time trend of global uterine cancer burden: an age-period-cohort analysis from 1990 to 2019 and predictions in a 25-year period","volume":"23","author":"Yang","year":"2023","journal-title":"BMC Womens Health"},{"key":"10.1016\/j.ijgc.2026.104839_bib3","doi-asserted-by":"crossref","DOI":"10.1155\/2022\/4070368","article-title":"Fertility-sparing approach in patients with endometrioid endometrial cancer Grade 2 stage IA (FIGO): a qualitative systematic review","volume":"2022","author":"Giampaolino","year":"2022","journal-title":"Biomed Res Int"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104839_bib4","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1136\/ijgc-2020-002230","article-title":"ESGO\/ESTRO\/ESP guidelines for the management of patients with endometrial carcinoma","volume":"31","author":"Concin","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104839_bib5","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1136\/ijgc-2022-004047","article-title":"ESGO\/ESHRE\/ESGE guidelines for the fertility-sparing treatment of patients with endometrial carcinoma","volume":"33","author":"Rodolakis","year":"2023","journal-title":"Int J Gynecol Cancer"},{"issue":"7","key":"10.1016\/j.ijgc.2026.104839_bib6","doi-asserted-by":"crossref","first-page":"1953","DOI":"10.1093\/humrep\/dem088","article-title":"Fertility-preserving treatment with progestin, and pathological criteria to predict responses, in young women with endometrial cancer","volume":"22","author":"Yamazawa","year":"2007","journal-title":"Hum Reprod"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104839_bib7","doi-asserted-by":"crossref","first-page":"84","DOI":"10.1272\/jnms.78.84","article-title":"Determining best potential predictor during high-dose progestin therapy for early staged and well-differentiated endometrial adenocarcinoma using semiquantitative analysis based on image processing and immunohistochemistry","volume":"78","author":"Kamoi","year":"2011","journal-title":"J Nippon Med Sch"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104839_bib8","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1016\/j.ygyno.2013.11.033","article-title":"Pathologic features associated with resolution of complex atypical hyperplasia and grade 1 endometrial adenocarcinoma after progestin therapy","volume":"132","author":"Gunderson","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104839_bib9","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1016\/j.ygyno.2015.10.015","article-title":"Prognostic factors of regression and relapse of complex atypical hyperplasia and well-differentiated endometrioid carcinoma with conservative treatment","volume":"139","author":"Yang","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104839_bib10","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1016\/j.ygyno.2015.10.023","article-title":"Downregulation of FOXO1 mRNA levels predicts treatment failure in patients with endometrial pathology conservatively managed with progestin-containing intrauterine devices","volume":"140","author":"Reyes","year":"2016","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104839_bib11","doi-asserted-by":"crossref","first-page":"191.e1","DOI":"10.1016\/j.ajog.2020.08.032","article-title":"Prospective phase II trial of levonorgestrel intrauterine device: nonsurgical approach for complex atypical hyperplasia and early-stage endometrial cancer","volume":"224","author":"Westin","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104839_bib12","doi-asserted-by":"crossref","first-page":"2025","DOI":"10.1007\/s00404-022-06398-3","article-title":"Analysis of immunohistochemical characteristics and recurrence after complete remission with fertility preservation treatment in patients with endometrial carcinoma and endometrial atypical hyperplasia","volume":"307","author":"Li","year":"2023","journal-title":"Arch Gynecol Obstet"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104839_bib13","doi-asserted-by":"crossref","first-page":"370.e1","DOI":"10.1016\/j.ajog.2020.10.003","article-title":"Mismatch repair status influences response to fertility-sparing treatment of endometrial cancer","volume":"224","author":"Chung","year":"2021","journal-title":"Am J Obstet Gynecol"},{"issue":"11","key":"10.1016\/j.ijgc.2026.104839_bib14","doi-asserted-by":"crossref","first-page":"1811","DOI":"10.1136\/ijgc-2020-001309","article-title":"Improving response to progestin treatment of low-grade endometrial cancer","volume":"30","author":"Baxter","year":"2020","journal-title":"Int J Gynecol Cancer"},{"key":"10.1016\/j.ijgc.2026.104839_bib15","doi-asserted-by":"crossref","first-page":"154","DOI":"10.1016\/j.ygyno.2024.04.013","article-title":"Mismatch repair deficiency and abnormal p53 expression has significant predictive value for progesterone resistance and endometrial tumorigenesis in patients with endometrial atypical hyperplasia receiving fertility-preserving treatment","volume":"186","author":"Peng","year":"2024","journal-title":"Gynecol Oncol"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104839_bib16","doi-asserted-by":"crossref","first-page":"1576","DOI":"10.1111\/1471-0528.14491","article-title":"Abnormal mismatch repair and other clinicopathologic predictors of poor response to progestin treatment in young women with endometrial complex atypical hyperplasia and well-differentiated endometrial adenocarcinoma: a consecutive case series","volume":"124","author":"Zakhour","year":"2017","journal-title":"BJOG"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104839_bib17","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/j.ygyno.2021.03.029","article-title":"Mismatch repair-deficiency specifically predicts recurrence of atypical endometrial hyperplasia and early endometrial carcinoma after conservative treatment: a multi-center study","volume":"161","author":"Raffone","year":"2021","journal-title":"Gynecol Oncol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104839_bib18","doi-asserted-by":"crossref","first-page":"e59","DOI":"10.3802\/jgo.2025.36.e59","article-title":"Fertility-sparing treatment outcomes using immune checkpoint inhibitors in endometrial cancer patients with Lynch syndrome","volume":"36","author":"Yang","year":"2025","journal-title":"J Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104839_bib19","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2024.35.e27","article-title":"Efficacy of fertility-sparing treatment with LNG-IUS is associated with different ProMisE subtypes of endometrial carcinoma or atypical endometrial hyperplasia","volume":"35","author":"Lv","year":"2024","journal-title":"J Gynecol Oncol"},{"issue":"6","key":"10.1016\/j.ijgc.2026.104839_bib20","doi-asserted-by":"crossref","first-page":"543","DOI":"10.1097\/PGP.0000000000000177","article-title":"Histologic effects of medroxyprogesterone acetate on endometrioid endometrial adenocarcinoma: a Gynecologic Oncology Group study","volume":"33","author":"Zaino","year":"2014","journal-title":"Int J Gynecol Pathol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104839_bib21","doi-asserted-by":"crossref","first-page":"252","DOI":"10.1186\/s12905-021-01383-5","article-title":"Significance of serum and pathological biomarkers in fertility-sparing treatment for endometrial cancer or atypical hyperplasia: a retrospective cohort study","volume":"21","author":"Wang","year":"2021","journal-title":"BMC Womens Health"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104839_bib22","doi-asserted-by":"crossref","first-page":"607","DOI":"10.1016\/j.ygyno.2014.06.014","article-title":"Anti-diabetic doses of metformin decrease proliferation markers in tumors of patients with endometrial cancer","volume":"134","author":"Laskov","year":"2014","journal-title":"Gynecol Oncol"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104839_bib23","doi-asserted-by":"crossref","first-page":"161","DOI":"10.1002\/cam4.353","article-title":"Antiproliferative and metabolic effects of metformin in a preoperative window clinical trial for endometrial cancer","volume":"4","author":"Schuler","year":"2015","journal-title":"Cancer Med"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104839_bib24","doi-asserted-by":"crossref","first-page":"466","DOI":"10.1016\/j.ygyno.2016.10.011","article-title":"Prospective evaluation of the molecular effects of metformin on the endometrium in women with newly diagnosed endometrial cancer: a window of opportunity study","volume":"143","author":"Soliman","year":"2016","journal-title":"Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104839_bib25","doi-asserted-by":"crossref","first-page":"104","DOI":"10.1016\/j.ejogrb.2018.10.025","article-title":"PTEN as a predictive marker of response to conservative treatment in endometrial hyperplasia and early endometrial cancer. A systematic review and meta-analysis","volume":"231","author":"Travaglino","year":"2018","journal-title":"Eur J Obstet Gynecol Reprod Biol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104839_bib32","doi-asserted-by":"crossref","first-page":"1086","DOI":"10.1111\/aogs.13587","article-title":"Immunohistochemical predictive markers of response to conservative treatment of endometrial hyperplasia and early endometrial cancer: a systematic review","volume":"98","author":"Travaglino","year":"2019","journal-title":"Acta Obstet Gynecol Scand"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104839_bib34","doi-asserted-by":"crossref","first-page":"494","DOI":"10.1097\/PGP.0000000000001008","article-title":"Predicting progestin therapy response with PTEN, PAX2, and \u03b2-catenin in patients with endometrioid precancer","volume":"43","author":"Liu","year":"2024","journal-title":"Int J Gynecol Pathol"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104839_bib35","doi-asserted-by":"crossref","DOI":"10.3802\/jgo.2023.34.e53","article-title":"PTEN mutation predicts unfavorable fertility preserving treatment outcome in the young patients with endometrioid endometrial cancer and atypical hyperplasia","volume":"34","author":"Xue","year":"2023","journal-title":"J Gynecol Oncol"},{"key":"10.1016\/j.ijgc.2026.104839_bib36","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2023.1282356","article-title":"Outcomes of fertility preservation treatments in patients with endometrial cancer with different molecular classifications based on an NGS panel","volume":"13","author":"Xu","year":"2023","journal-title":"Front Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104839_bib37","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1186\/s12943-023-01827-6","article-title":"PI3K\/AKT\/mTOR signaling transduction pathway and targeted therapies in cancer","volume":"22","author":"Glaviano","year":"2023","journal-title":"Mol Cancer"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104839_bib38","doi-asserted-by":"crossref","first-page":"320","DOI":"10.3390\/cancers17020320","article-title":"From genes to clinical practice: exploring the genomic underpinnings of endometrial cancer","volume":"17","author":"Molefi","year":"2025","journal-title":"Cancers (Basel)"},{"issue":"7447","key":"10.1016\/j.ijgc.2026.104839_bib39","doi-asserted-by":"crossref","first-page":"67","DOI":"10.1038\/nature12113","article-title":"Integrated genomic characterization of endometrial carcinoma","volume":"497","author":"Cancer Genome Atlas Research Network","year":"2013","journal-title":"Nature"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104839_bib40","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1007\/s11912-022-01326-9","article-title":"Targeting the PI3K pathway in gynecologic malignancies","volume":"24","author":"Avila","year":"2022","journal-title":"Curr Oncol Rep"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104839_bib41","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1016\/j.ygyno.2021.12.031","article-title":"A randomized phase II trial of everolimus and letrozole or hormonal therapy in women with advanced, persistent or recurrent endometrial carcinoma: a GOG Foundation study","volume":"164","author":"Slomovitz","year":"2022","journal-title":"Gynecol Oncol"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104839_bib42","first-page":"41","article-title":"Hormone therapy plus mTOR inhibitors in the treatment of endometrial carcinoma","volume":"9","author":"Stringer","year":"2013","journal-title":"Oncol Hematol Rev"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104839_bib43","doi-asserted-by":"crossref","first-page":"775","DOI":"10.1007\/s10787-022-00980-6","article-title":"The role of AMPK-dependent pathways in cellular and molecular mechanisms of metformin: a new perspective for treatment and prevention of diseases","volume":"30","author":"Hasanvand","year":"2022","journal-title":"Inflammopharmacology"},{"issue":"7899","key":"10.1016\/j.ijgc.2026.104839_bib44","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1038\/s41586-022-04431-8","article-title":"Low-dose metformin targets the lysosomal AMPK pathway through PEN2","volume":"603","author":"Ma","year":"2022","journal-title":"Nature"},{"key":"10.1016\/j.ijgc.2026.104839_bib45","doi-asserted-by":"crossref","DOI":"10.1016\/j.biopha.2019.108712","article-title":"Metformin sensitizes endometrial cancer cells to progestin by targeting TET1 to downregulate glyoxalase I expression","volume":"113","author":"Jiang","year":"2019","journal-title":"Biomed Pharmacother"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104839_bib46","doi-asserted-by":"crossref","first-page":"262","DOI":"10.1093\/annonc\/mdv539","article-title":"Phase II study of medroxyprogesterone acetate plus metformin as a fertility-sparing treatment for atypical endometrial hyperplasia and endometrial cancer","volume":"27","author":"Mitsuhashi","year":"2016","journal-title":"Ann Oncol"},{"issue":"12","key":"10.1016\/j.ijgc.2026.104839_bib47","doi-asserted-by":"crossref","first-page":"1499","DOI":"10.1136\/ijgc-2021-002699","article-title":"Outcomes of women treated with progestin and metformin for atypical endometrial hyperplasia and early endometrial cancer: a systematic review and meta-analysis","volume":"31","author":"Chae-Kim","year":"2021","journal-title":"Int J Gynecol Cancer"},{"issue":"5","key":"10.1016\/j.ijgc.2026.104839_bib48","doi-asserted-by":"crossref","first-page":"1502","DOI":"10.3390\/jcm9051502","article-title":"Different shades of L1CAM in the pathophysiology of cancer stem cells","volume":"9","author":"Giordano","year":"2020","journal-title":"J Clin Med"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104839_bib49","first-page":"2792","article-title":"L1CAM promotes epithelial to mesenchymal transition and formation of cancer initiating cells in human endometrial cancer","volume":"15","author":"Chen","year":"2018","journal-title":"Exp Ther Med"},{"issue":"10","key":"10.1016\/j.ijgc.2026.104839_bib50","doi-asserted-by":"crossref","first-page":"4585","DOI":"10.3390\/ijms26104585","article-title":"Phosphoproteomics reveals L1CAM-associated signaling networks in high-grade serous ovarian carcinoma: implications for radioresistance and tumorigenesis","volume":"26","author":"Todorov","year":"2025","journal-title":"Int J Mol Sci"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104839_bib51","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1038\/s41416-018-0187-6","article-title":"L1CAM further stratifies endometrial carcinoma patients with no specific molecular risk profile","volume":"119","author":"Kommoss","year":"2018","journal-title":"Br J Cancer"},{"key":"10.1016\/j.ijgc.2026.104839_bib52","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1016\/j.ygyno.2025.07.020","article-title":"The challenge of molecular stratification in no specific molecular profile endometrial cancer","volume":"200","author":"Marchetti","year":"2025","journal-title":"Gynecol Oncol"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104839_bib53","doi-asserted-by":"crossref","first-page":"789","DOI":"10.1007\/s00404-023-07149-8","article-title":"The role of L1CAM as predictor of poor prognosis in stage I endometrial cancer: a systematic review and meta-analysis","volume":"309","author":"Giannini","year":"2024","journal-title":"Arch Gynecol Obstet"},{"issue":"8","key":"10.1016\/j.ijgc.2026.104839_bib54","doi-asserted-by":"crossref","first-page":"941","DOI":"10.1111\/1471-0528.17417","article-title":"Serum HE4 predicts progestin treatment response in endometrial cancer and atypical hyperplasia: a prognostic study","volume":"130","author":"Barr","year":"2023","journal-title":"BJOG"},{"issue":"2","key":"10.1016\/j.ijgc.2026.104839_bib55","doi-asserted-by":"crossref","first-page":"276","DOI":"10.3390\/cancers12020276","article-title":"Baseline serum HE4 but not tissue HE4 expression predicts response to the levonorgestrel-releasing intrauterine system in atypical hyperplasia and early stage endometrial cancer","volume":"12","author":"Behrouzi","year":"2020","journal-title":"Cancers (Basel)"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104839_bib56","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1016\/j.ygyno.2014.11.008","article-title":"Dual-specificity phosphatase 6 predicts the sensitivity of progestin therapy for atypical endometrial hyperplasia","volume":"136","author":"Zhang","year":"2015","journal-title":"Gynecol Oncol"},{"issue":"9","key":"10.1016\/j.ijgc.2026.104839_bib57","doi-asserted-by":"crossref","first-page":"10363","DOI":"10.18632\/oncotarget.7004","article-title":"Mechanism of progestin resistance in endometrial precancer\/cancer through Nrf2-AKR1C1 pathway","volume":"7","author":"Wang","year":"2016","journal-title":"Oncotarget"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104839_bib58","doi-asserted-by":"crossref","first-page":"561","DOI":"10.1097\/IGC.0b013e31824927db","article-title":"Identification of differentially expressed microRNAs in endometrial cancer cells after progesterone treatment","volume":"22","author":"Bae","year":"2012","journal-title":"Int J Gynecol Cancer"},{"issue":"4","key":"10.1016\/j.ijgc.2026.104839_bib59","doi-asserted-by":"crossref","first-page":"257","DOI":"10.1007\/s12672-017-0295-4","article-title":"Panobinostat enhances growth suppressive effects of progestin on endometrial carcinoma by increasing progesterone receptor and mitogen-inducible Gene-6","volume":"8","author":"Ando","year":"2017","journal-title":"Horm Cancer"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104839_bib60","first-page":"11","article-title":"Outcome of fertility-sparing treatment with medroxyprogesterone acetate for atypical hyperplasia and endometrial carcinoma in young Japanese women","volume":"35","author":"Kataoka","year":"2014","journal-title":"Eur J Gynaecol Oncol"},{"issue":"23","key":"10.1016\/j.ijgc.2026.104839_bib61","doi-asserted-by":"crossref","first-page":"8258","DOI":"10.1158\/1078-0432.CCR-05-1189","article-title":"Identification of a novel estrogen-regulated gene, EIG121, induced by hormone replacement therapy and differentially expressed in type I and type II endometrial cancer","volume":"11","author":"Deng","year":"2005","journal-title":"Clin Cancer Res."},{"issue":"4","key":"10.1016\/j.ijgc.2026.104839_bib62","doi-asserted-by":"crossref","first-page":"637","DOI":"10.1038\/s41588-024-01703-z","article-title":"Proteogenomic insights into early-onset endometrioid endometrial carcinoma: predictors for fertility-sparing therapy response","volume":"56","author":"Hu","year":"2024","journal-title":"Nat Genet"},{"key":"10.1016\/j.ijgc.2026.104839_bib63","doi-asserted-by":"crossref","DOI":"10.1016\/j.compbiomed.2025.109764","article-title":"Prediction of a radiomics-based nomogram for complete remission in atypical endometrial hyperplasia and early endometrial cancer patients seeking fertility preservation","volume":"187","author":"Wang","year":"2025","journal-title":"Comput Biol Med"},{"issue":"1","key":"10.1016\/j.ijgc.2026.104839_bib64","doi-asserted-by":"crossref","first-page":"583","DOI":"10.1186\/s12905-023-02730-4","article-title":"Urine metabolomics for assessing fertility-sparing treatment efficacy in endometrial cancer: a non-invasive approach using ultra-performance liquid chromatography mass spectrometry","volume":"23","author":"Chen","year":"2023","journal-title":"BMC Womens Health"},{"issue":"3","key":"10.1016\/j.ijgc.2026.104839_bib65","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1016\/j.ygyno.2022.04.008","article-title":"Volumetric apparent diffusion coefficient (ADC) histogram metrics as imaging biomarkers for pretreatment predicting response to fertility-sparing treatment in patients with endometrial cancer","volume":"165","author":"Ma","year":"2022","journal-title":"Gynecol Oncol"}],"container-title":["International Journal of Gynecological Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26003701?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S1048891X26003701?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T20:48:06Z","timestamp":1788814086000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S1048891X26003701"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9]]},"references-count":58,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026,9]]}},"alternative-id":["S1048891X26003701"],"URL":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104839","relation":{},"ISSN":["1048-891X"],"issn-type":[{"value":"1048-891X","type":"print"}],"subject":[],"published":{"date-parts":[[2026,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Biomarkers guiding fertility-sparing treatment in endometrial cancer","name":"articletitle","label":"Article Title"},{"value":"International Journal of Gynecological Cancer","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ijgc.2026.104839","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2026 European Society of Gynaecological Oncology and the International Gynecologic Cancer Society. Published by Elsevier Inc. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"104839"}}